A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Published:October 14, 2020DOI:



      Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET–positive squamous cell carcinoma (SCC).

      Patients and Methods

      Patients with previously treated SCC with c-MET–positive tumors (H score ≥ 150, Ventana SP44 assay) were enrolled into 2 cohorts: Cohort 1 (immune checkpoint inhibitor-naive) and Cohort 2 (immune checkpoint inhibitor refractory). Telisotuzumab vedotin 2.7 mg/kg was administered intravenously every 3 weeks until disease progression or unacceptable toxicity. Response assessments were performed every 6 weeks. The primary endpoint was response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary endpoints included progression-free survival, overall survival, response within cohort, duration of response, and toxicities. Interim analysis was planned after 20 evaluable patients, with ≥ 3 responses needed to continue enrollment.


      Forty-nine patients (14% of screened patients) were assigned to S1400K, 28 patients enrolled (15 in Cohort 1 and 13 in Cohort 2), and 23 were eligible. S1400K closed on December 21, 2018 owing to lack of efficacy. Two responses (response rate of 9%; 95% confidence interval, 0%-20%) were reported in cohort 1 (1 complete and 1 unconfirmed partial response), whereas 10 patients had stable disease, with a disease control rate of 52%. The median overall and progression-free survival was 5.6 and 2.4 months, respectively. There were 3 grade 5 events (2 pneumonitis, in Cohort 2, and 1 bronchopulmonary hemorrhage, in Cohort 1).


      Telisotuzumab vedotin failed to meet the pre-specified response needed to justify continuing enrollment to S1400K. Pneumonitis was an unanticipated toxicity observed in patients with SCC.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Herbst R.S.
        • Gandara D.R.
        • Hirsch F.R.
        • et al.
        Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400.
        Clin Cancer Res. 2015; 21: 1514-1524
        • Malik S.M.
        • Pazdur R.
        • Abrams J.S.
        • et al.
        Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of “master protocols” in lung cancer.
        J Thorac Oncol. 2014; 9: 1443-1448
        • Ma P.C.
        • Maulik G.
        • Christensen J.
        • Salgia R.
        c-Met: structure, functions and potential for therapeutic inhibition.
        Cancer Metastasis Rev. 2003; 22: 309-325
        • Park M.
        • Dean M.
        • Kaul K.
        • Braun M.J.
        • Gonda M.A.
        • Vande Woude G.
        Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.
        Proc Natl Acad Sci U S A. 1987; 84: 6379-6383
        • Sadiq A.A.
        • Salgia R.
        MET as a possible target for non-small-cell lung cancer.
        J Clin Oncol. 2013; 31: 1089-1096
        • Birchmeier C.
        • Gherardi E.
        Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase.
        Trends Cell Biol. 1998; 8: 404-410
        • Gherardi E.
        • Birchmeier W.
        • Birchmeier C.
        • Vande Woude G.
        Targeting MET in cancer: rationale and progress.
        Nat Rev Cancer. 2012; 12: 89-103
        • Waqar S.N.
        • Morgensztern D.
        • Sehn J.
        MET mutation associated with responsiveness to crizotinib.
        J Thorac Oncol. 2015; 10: e29-e31
        • Edelman M.
        • Spigel D.
        • O’Byrne K.
        • et al.
        The prevalence of MET expression by immunohistochemistry (IHC) in the MetLung (OAM4971g) trial: a randomized, placebo-controlled, phase III study with erlotinib + onartuzumab (MetMab) vs erlotinib + placebo in patients with previously treated non-small cell lung cancer.
        J Thorac Oncol. 2013; 8 (Abstract MO1312.1307): S2-S1348
        • Dziadziuszko R.
        • Wynes M.W.
        • Singh S.
        • et al.
        Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
        J Thorac Oncol. 2012; 7: 340-347
        • Gao J.
        • Aksoy B.A.
        • Dogrusoz U.
        • et al.
        Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
        Sci Signal. 2013; 6: pl1
        • Schildhaus H.U.
        • Schultheis A.M.
        • Ruschoff J.
        • et al.
        MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung.
        Clin Cancer Res. 2015; 21: 907-915
        • Mok T.S.
        • Geater S.L.
        • Su W.C.
        • et al.
        A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in Asian patients with advanced stage pulmonary adenocarcinoma.
        J Thorac Oncol. 2016; 11: 1736-1744
        • Spigel D.R.
        • Ervin T.J.
        • Ramlau R.A.
        • et al.
        Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
        J Clin Oncol. 2013; 31: 4105-4114
        • Scagliotti G.
        • von Pawel J.
        • Novello S.
        • et al.
        Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer.
        J Clin Oncol. 2015; 33: 2667-2674
        • Wang J.
        • Anderson M.G.
        • Oleksijew A.
        • et al.
        ABBV-399, a c-Met antibody drug conjugate that targets both MET amplified and c-Met overexpressing tumors, irrespective of MET pathway dependence.
        Clin Cancer Res. 2016; 23: 992-1000
        • Strickler J.H.
        • LoRusso P.
        • Yen C.-J.
        • et al.
        Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.
        J Clin Oncol. 2014; 32: 2507
        • Kang Y.-K.
        • LoRusso P.
        • Salgia R.
        • et al.
        Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).
        J Clin Oncol. 2015; 33: 167
        • Strickler J.H.
        • Weekes C.D.
        • Nemunaitis J.
        • et al.
        First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors.
        J Clin Oncol. 2018; 36: 3298-3306
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Watermann I.
        • Schmitt B.
        • Stellmacher F.
        • et al.
        Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?.
        Diagn Pathol. 2015; 10: 130
        • Hirsch F.R.
        • Bunn Jr., P.A.
        • Herbst R.S.
        “Companion diagnostics:” has their time come and gone?.
        Clin Cancer Res. 2014; 20: 4422-4424
        • Organ S.L.
        • Tsao M.S.
        An overview of the c-MET signaling pathway.
        Ther Adv Med Oncol. 2011; 3: S7-S19
        • Sabet Y.
        • Ramirez S.
        • Rosell Cespedes E.
        • et al.
        Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory Hodgkin’s lymphoma.
        Case Rep Pulmonol. 2016; 2016: 2359437
        • Egloff H.
        • Kidwell K.M.
        • Schott A.
        Ado-trastuzumab emtansine-induced pulmonary toxicity: a single-institution retrospective review.
        Case Rep Oncol. 2018; 11: 527-533
        • Boyle T.A.
        • Khalil F.K.
        • Mino-Kenudson M.
        • et al.
        • Lung Cancer Mutation Consortium (LCMC) Pathologist Panel Group
        Round robin evaluation of MET protein expression in lung adenocarcinomas improves interobserver concordance.
        Appl Immunohistochem Mol Morphol. 2019;
        • Guo R.
        • Berry L.D.
        • Aisner D.L.
        • et al.
        MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer Mutation Consortium.
        J Thorac Oncol. 2019; 14: 1666-1671